Choosing the Right library prep for Low-Input RNA-Seq
In transcriptomics, sample quality often dictates experimental success. When working with ultra-low input samples, you rarely have the luxury of a “perfect” starting material.
In transcriptomics, sample quality often dictates experimental success. When working with ultra-low input samples, you rarely have the luxury of a “perfect” starting material.
If you work with clinical biobanks or archived human tissues, you know that Formalin-Fixed, Paraffin-Embedded (FFPE) tissue blocks are a scientific goldmine. They hold decades of patient history, treatment outcomes, and clinical endpoints.
When your entire experiment relies on a few hundred laser-captured cells, a rare circulating tumor cell population, or a handful of precious fluorescence-activated cell sorting (FACS) isolates, the stakes at the laboratory bench are exceptionally high.
When designing a transcriptomics experiment, researchers focus deeply on biological variables: choosing the right time points, establishing robust controls, and ensuring sufficient biological replicates.
Every molecular biologist knows the unique anxiety of submitting samples for next-generation sequencing. You have spent weeks, perhaps months, culturing cells, dosing animal models, or meticulously microdissecting tissues.
Navigating the spatial biology landscape can feel like standing in front of a massive soundboard, trying to balance dozens of sliders at once. Every platform promises single-cell or near single-cell resolution,
but each hits that benchmark through fundamentally different engineering.
In genomic research, mapping structural chromatin accessibility (scATAC-Seq) or sequencing cellular transcripts (scRNA-Seq) from separate cell aliquots provides an informative, yet fractured, perspective.
When designing a single-cell transcriptomics study, selecting the appropriate assay chemistry determines how you collect samples, manage budgets, and structure your data.
Choosing the right single-cell technology is one of the most critical decisions in modern genomic experimental design. Selecting an mismatched platform doesn’t just inflate sequencing costs—it can actively bias your data by destroying fragile cell types, failing to capture rare cell variants, or missing critical splice isoforms.
Proteomics has never offered more ways to measure the proteome, and that abundance of choice is exactly what makes method selection difficult. Mass spectrometry, targeted assays, and affinity-based platforms each measure proteins in fundamentally different ways, and no single approach is best for every question.